Therapeutic Drug Monitoring (TDM) of antitumor necrosis factor (TNF) such as Adalimumab has increased over time as doctors improve their treatment of IBD. Even if the medication is administered subcutaneously by the patient, there is a need to check trough levels before medication to ensure proper levels are maintained. However, obtaining results from previously available testing methods take days or even weeks.
Procise ADL allows for true point-of-care testing of Adalimumab levels in under 5 minutes with finger stick blood. So during a standard visit with an IBD patient, a physician or technician can check their levels and adjust medication accordingly. During their very next injection, not weeks or months later.
Product Information
| Product Information | |
|---|---|
| Sample Types | Finger prick whole blood, venous blood, or serum |
| Reportable Range | 1.3μg/mL - 51.5μg/mL |
| Time to Results | Less than 5 minutes |
| Stability | 2 years at room temperature |
| Validated for | Adalimumab (Humira®, Amjevita®, and Imraldi®) |
Calibrated against WHO standard.
Performance
Precision
| Level | Avg[ADL]μg/mL | %CV |
|---|---|---|
| Low QC | 2.8 | 3.5% |
| High QC | 20.4 | 3.7% |
| Low Serum | 4.7 | 3.7% |
| Med Serum | 9.1 | 3.5% |
| High Serum | 38.9 | 3.9% |
Ordering Information
| Item | Cat # | Description | #/Kit |
|---|---|---|---|
| ADL Assay | 4853 | Kit for conducting assays | 20 |
| In addition to 20 tests, the kit includes: | |||
| 4403 | Buffer bulbs | 20 | |
| 4868 | ADL controls | 2 hi and low | |
| 4552 | Whole blood pipettes | 20 |
“Being able to proactively monitor drug levels is very attractive. Today we don’t check very often, but if it were fast and affordable, then it could help me manage my patients more effectively.”
Contact Us
To learn more about our assays or to speak with our team, please contact us here or email info@procisediagnostics.com.